Annual EBITDA
-$24.25 M
+$4.06 M+14.34%
December 31, 2024
Summary
- As of March 13, 2025, APVO annual EBITDA is -$24.25 million, with the most recent change of +$4.06 million (+14.34%) on December 31, 2024.
- During the last 3 years, APVO annual EBITDA has fallen by -$3.99 million (-19.72%).
- APVO annual EBITDA is now -19.72% below its all-time high of -$20.26 million, reached on December 31, 2021.
Performance
APVO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$6.31 M
-$1.18 M-23.05%
December 31, 2024
Summary
- As of March 13, 2025, APVO quarterly EBITDA is -$6.31 million, with the most recent change of -$1.18 million (-23.05%) on December 31, 2024.
- Over the past year, APVO quarterly EBITDA has stayed the same.
- APVO quarterly EBITDA is now -66.78% below its all-time high of -$3.78 million, reached on December 31, 2021.
Performance
APVO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$24.25 M
-$43.00 K-0.18%
December 31, 2024
Summary
- As of March 13, 2025, APVO TTM EBITDA is -$24.25 million, with the most recent change of -$43.00 thousand (-0.18%) on December 31, 2024.
- Over the past year, APVO TTM EBITDA has stayed the same.
- APVO TTM EBITDA is now -130.69% below its all-time high of -$10.51 million, reached on March 31, 2015.
Performance
APVO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
APVO EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +14.3% | 0.0% | 0.0% |
3 y3 years | -19.7% | 0.0% | 0.0% |
5 y5 years | +37.4% | 0.0% | 0.0% |
APVO EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -19.7% | +14.3% | -66.8% | +21.4% | -27.4% | +21.0% |
5 y | 5-year | -19.7% | +37.4% | -66.8% | +21.4% | -27.4% | +37.4% |
alltime | all time | -19.7% | +62.3% | -66.8% | +65.5% | -130.7% | +59.7% |
Aptevo Therapeutics EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | -$24.25 M(-14.3%) | -$6.31 M(+23.0%) | -$24.25 M(+0.2%) |
Sep 2024 | - | -$5.13 M(-13.6%) | -$24.21 M(-5.1%) |
Jun 2024 | - | -$5.93 M(-13.7%) | -$25.52 M(-7.6%) |
Mar 2024 | - | -$6.88 M(+9.7%) | -$27.61 M(-2.5%) |
Dec 2023 | -$28.31 M(+2.1%) | -$6.27 M(-2.6%) | -$28.31 M(-4.2%) |
Sep 2023 | - | -$6.44 M(-19.8%) | -$29.57 M(-3.7%) |
Jun 2023 | - | -$8.03 M(+5.9%) | -$30.69 M(+2.5%) |
Mar 2023 | - | -$7.58 M(+0.7%) | -$29.95 M(+8.0%) |
Dec 2022 | -$27.74 M(+36.9%) | -$7.52 M(-0.5%) | -$27.74 M(+15.6%) |
Sep 2022 | - | -$7.56 M(+3.8%) | -$24.00 M(+14.9%) |
Jun 2022 | - | -$7.29 M(+35.7%) | -$20.89 M(+9.8%) |
Mar 2022 | - | -$5.37 M(+41.9%) | -$19.03 M(-6.0%) |
Dec 2021 | -$20.26 M(-22.4%) | -$3.78 M(-15.1%) | -$20.26 M(-11.7%) |
Sep 2021 | - | -$4.46 M(-17.8%) | -$22.95 M(-6.1%) |
Jun 2021 | - | -$5.42 M(-17.8%) | -$24.44 M(-4.2%) |
Mar 2021 | - | -$6.59 M(+1.8%) | -$25.52 M(-2.2%) |
Dec 2020 | -$26.09 M(-32.6%) | -$6.48 M(+8.9%) | -$26.09 M(-3.4%) |
Sep 2020 | - | -$5.95 M(-8.5%) | -$27.01 M(-15.5%) |
Jun 2020 | - | -$6.50 M(-9.3%) | -$31.98 M(-9.4%) |
Mar 2020 | - | -$7.17 M(-3.2%) | -$35.31 M(-8.8%) |
Dec 2019 | -$38.73 M | -$7.40 M(-32.2%) | -$38.73 M(-12.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2019 | - | -$10.91 M(+11.0%) | -$44.31 M(-1.4%) |
Jun 2019 | - | -$9.83 M(-7.1%) | -$44.93 M(-4.3%) |
Mar 2019 | - | -$10.58 M(-18.5%) | -$46.94 M(-4.7%) |
Dec 2018 | -$49.27 M(-3.0%) | -$12.99 M(+12.6%) | -$49.27 M(-7.0%) |
Sep 2018 | - | -$11.53 M(-2.7%) | -$52.97 M(+4.9%) |
Jun 2018 | - | -$11.84 M(-8.3%) | -$50.52 M(-3.7%) |
Mar 2018 | - | -$12.91 M(-22.6%) | -$52.45 M(+3.2%) |
Dec 2017 | -$50.82 M(-21.1%) | -$16.68 M(+83.9%) | -$50.82 M(+0.5%) |
Sep 2017 | - | -$9.07 M(-34.1%) | -$50.55 M(-15.5%) |
Jun 2017 | - | -$13.77 M(+22.0%) | -$59.80 M(+3.1%) |
Mar 2017 | - | -$11.29 M(-31.2%) | -$57.99 M(-1.5%) |
Dec 2016 | -$64.40 M(+10.7%) | -$16.42 M(-10.4%) | -$58.84 M(-2.1%) |
Sep 2016 | - | -$18.32 M(+53.1%) | -$60.12 M(+10.9%) |
Jun 2016 | - | -$11.96 M(-1.5%) | -$54.20 M(-9.4%) |
Mar 2016 | - | -$12.14 M(-31.4%) | -$59.83 M(+2.8%) |
Dec 2015 | -$58.19 M(+17.6%) | -$17.69 M(+42.7%) | -$58.19 M(+43.7%) |
Sep 2015 | - | -$12.40 M(-29.5%) | -$40.50 M(+44.1%) |
Jun 2015 | - | -$17.59 M(+67.4%) | -$28.10 M(+167.4%) |
Mar 2015 | - | -$10.51 M | -$10.51 M |
Dec 2014 | -$49.47 M(-6.1%) | - | - |
Dec 2013 | -$52.69 M | - | - |
FAQ
- What is Aptevo Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aptevo Therapeutics?
- What is Aptevo Therapeutics annual EBITDA year-on-year change?
- What is Aptevo Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aptevo Therapeutics?
- What is Aptevo Therapeutics quarterly EBITDA year-on-year change?
- What is Aptevo Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aptevo Therapeutics?
- What is Aptevo Therapeutics TTM EBITDA year-on-year change?
What is Aptevo Therapeutics annual EBITDA?
The current annual EBITDA of APVO is -$24.25 M
What is the all time high annual EBITDA for Aptevo Therapeutics?
Aptevo Therapeutics all-time high annual EBITDA is -$20.26 M
What is Aptevo Therapeutics annual EBITDA year-on-year change?
Over the past year, APVO annual EBITDA has changed by +$4.06 M (+14.34%)
What is Aptevo Therapeutics quarterly EBITDA?
The current quarterly EBITDA of APVO is -$6.31 M
What is the all time high quarterly EBITDA for Aptevo Therapeutics?
Aptevo Therapeutics all-time high quarterly EBITDA is -$3.78 M
What is Aptevo Therapeutics quarterly EBITDA year-on-year change?
Over the past year, APVO quarterly EBITDA has changed by $0.00 (0.00%)
What is Aptevo Therapeutics TTM EBITDA?
The current TTM EBITDA of APVO is -$24.25 M
What is the all time high TTM EBITDA for Aptevo Therapeutics?
Aptevo Therapeutics all-time high TTM EBITDA is -$10.51 M
What is Aptevo Therapeutics TTM EBITDA year-on-year change?
Over the past year, APVO TTM EBITDA has changed by $0.00 (0.00%)